Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of Leukocytes

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.

Haemophilia : the official journal of the World Federation of Hemophilia·2011

Same author

Immune tolerance induction for a patient with factor IX inhibitors--a case report.

Haemophilia : the official journal of the World Federation of Hemophilia·2010

Same author

Undetected factor VIII in a patient with type 3 von Willebrands disease mistaken as severe haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2009

Same author

Right atrial catheters in children with cancer: a decade of experience in the use of tunnelled, exteriorized devices at a single institution.

The American journal of pediatric hematology/oncology·1991

Same author

Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·1989

Same author

Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura.

British journal of haematology·1987

Search research articles

Related Experiment Video

Updated: Jun 4, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Acute leukemias in children.

Canadian Family Physician Medecin De Famille Canadien

|February 8, 2011

Summary

This summary is machine-generated.

Combination chemotherapy offers a cure for lymphoblastic leukemia in 50% of children. Advanced techniques identify treatment failures, while immunotherapy and bone marrow transplants are explored for acute non-lymphocytic leukemia. Specialized centers are crucial for complex childhood cancer management.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: Jun 4, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Area of Science:

Pediatric Oncology
Hematology
Immunology

Background:

Combination chemotherapy improves survival rates for lymphoblastic leukemia (LL) in children, offering realistic hopes for a cure.
Sophisticated cytochemical and immunological techniques aid in identifying factors contributing to treatment failures in pediatric leukemias.
Survival rates for acute non-lymphocytic leukemia (ANLL) remain poor despite novel treatment strategies.

Purpose of the Study:

To highlight advancements in pediatric leukemia treatment, focusing on survival rates and emerging therapeutic approaches.
To emphasize the importance of understanding factors influencing treatment outcomes in childhood leukemias.
To advocate for specialized centers in managing complex pediatric malignancies.

Main Methods:

Review of current treatment regimens and survival data for childhood lymphoblastic leukemia and acute non-lymphocytic leukemia.
Discussion of advanced diagnostic techniques, including cytochemical and immunological methods.
Exploration of novel therapeutic modalities such as immunotherapy and bone marrow transplantation.

Main Results:

Approximately 50% of children with lymphoblastic leukemia achieve long-term survival (≥5 years) with combination chemotherapy.
Identification of predisposing factors for treatment failure through advanced diagnostic techniques.
Continued poor survival outcomes for acute non-lymphocytic leukemia necessitate further research.

Conclusions:

While lymphoblastic leukemia shows improved outcomes, acute non-lymphocytic leukemia requires innovative treatment strategies.
Manipulation of host-tumor immune response, including immunotherapy and bone marrow transplantation, represents a promising research direction.
Complex treatment regimens underscore the necessity for specialized pediatric cancer centers for optimal diagnosis and management.